FDA ex­perts wave through Pfiz­er's copy­cat of an ane­mia med from Am­gen, J&J, but a le­gal chal­lenge still re­mains

Pfiz­er had no prob­lem con­vinc­ing an ex­pert pan­el at the FDA that its biosim­i­lar of Am­gen’s block­buster ane­mia med Epogen and Pr­o­crit, mar­ket­ed by J …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.